Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TK1 | P04183 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | PYGM | P11217 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7105434 | 0.85 | SMN1; SMN2 (0.44) | SMN1; SMN2ALDH1A1POLBKMT2ATK1 | |
| SCHEMBL9223679 | 0.83 | SMN1; SMN2 (0.49) | SMN1; SMN2ALDH1A1POLBKMT2ATK1 | |
| SCHEMBL5052899 | 0.83 | SMN1; SMN2 (0.49) | SMN1; SMN2ALDH1A1POLBKMT2ATK1 | |
| SCHEMBL3066357 | 0.77 | SMN1; SMN2 (0.45) | SMN1; SMN2ALDH1A1POLBKMT2ATK1 | |
| SCHEMBL3087369 | 0.76 | SMN1; SMN2 (0.45) | SMN1; SMN2ALDH1A1POLBKMT2ATK1 | |
| SCHEMBL3085890 | 0.76 | SMN1; SMN2 (0.44) | SMN1; SMN2ALDH1A1POLBKMT2ATK1 | |
| SCHEMBL3080556 | 0.76 | TK1 (0.46) | SMN1; SMN2ALDH1A1POLBKMT2ATK1 | |
| SCHEMBL3076874 | 0.76 | SMN1; SMN2 (0.44) | SMN1; SMN2ALDH1A1POLBKMT2ATK1 | |
| SCHEMBL10388601 | 0.75 | TK1 (0.41) | SMN1; SMN2ALDH1A1POLBKMT2ATK1 | |
| SCHEMBL3084357 | 0.74 | SMN1; SMN2 (0.43) | SMN1; SMN2ALDH1A1POLBKMT2ATK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030207824-A1 | Pyrimidine derivatives for labeled binding partners | MATTEUCCI MARK D (US) | 2003-11-06 | — | — | US | disclosed |
| US-6617437-B1 | Modified oligonucleotide of given formula; useful in diagnostics and therapeutics | ISIS PHARMACEUTICALS, INC. | 2003-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207824-A1 | Pyrimidine derivatives for labeled binding partners | HNRNPH3, NSUN2, HNRNPH1 | SMN1; SMN2 1543/4885ALDH1A1 2764/4885POLB 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.